Commentary: New York must take on Big Pharma by demanding more transparency in pricing and ensuring generics aren't delayed ...

Mallinckrodt PLC, an Irish pharmaceutical company with a big footprint and long history in the St. Louis area, will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion.

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal, valuing the combined pharmaceutical company at $6.7 billion, writes John George for the Philadelphia Business Journal ...

Mallinckrodt, the Irish pharmaceutical company with its U.S. headquarters in Hazelwood, has agreed to merge with drug maker ...

When the deal closes, Endo will become a wholly owned subsidiary of Mallinckrodt. The combined company will take on a yet-to-be-determined name and is expected to trade on the New ...

Pharmaceutical companies Mallinckrodt Pharmaceuticals Plc and Endo Inc. have signed an agreement to create a combined company worth $6.7 billion. This is reported in a joint press release. Under the ...

Endo, Inc. (OTCQX: NDOI) has announced a definitive agreement to divest its International Pharmaceuticals business, operated primarily through Canada-based Paladin Pharma Inc., to Knight Therapeutics ...

Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after ...

Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said Thursday that Endo shareholders will receive a total of $80 million in cash and ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...